Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
National Alliance for Research on Schizophrenia and Depression
Cephalon
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women age 18-65 years
Patients with Diagnostic and Statistical Manual (DSM-IV) defined schizophrenia or schizoaffective disorder
Treated with any atypical antipsychotic for at least 2 months
Patients with documented weight gain \> 7% with current antipsychotic medication
Able to provide written consent
You may not be if
Women who are pregnant or nursing. Female participants must have a negative urine pregnancy test at screening.
DSM-IV defined substance or alcohol dependence within the 2 months preceding the start of the trial
Treatment with a monoamine oxidase inhibitor (e.g., tranylcypromine, phenelzine, isocarboxazid) within 2 weeks of starting the trial
Patients considered at high risk for suicide or violence
Patients with history of or symptoms on systems review consistent with clinically significant and currently relevant hematologic, renal, hepatic, gastrointestinal, endocrine, pulmonary, dermatologic, oncologic or neurologic (including seizures or epilepsy) disease
Patients with a history of or symptoms on systems review consistent with significant cardiovascular disease, bypass surgery, or concurrent cardiovascular disease, including uncontrolled hypertension, hypotension, congestive heart failure, angina pectoris, or recent (within last 6 months) myocardial infarction
Use of any investigational drug within 4 weeks before screening
History of hypersensitivity or other intolerable adverse effects to modafinil
Patients who experience severe sleep disturbances from modafinil
Clareo Health | Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
